文献速递青光眼

Wnt抑制后激活可恢复小梁网细胞正常表型

Wnt Activation After Inhibition Restores Trabecular Meshwork Cells Toward a Normal Phenotype.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

该研究在非青光眼供体来源的原代人小梁网细胞中,先以LGK974抑制Wnt通路9天,再以LY2090314激活Wnt通路3天,发现Wnt激活可逆转Wnt抑制引起的细胞骨架改变、细胞刚度升高及细胞外基质相关基因表达异常,提示Wnt激活可能成为降低眼压的治疗策略。

要点

  • Wnt抑制导致小梁网细胞F-actin改变和细胞刚度升高至11.86 kPa。
  • 后续Wnt激活使细胞刚度降至4.195 kPa,并恢复细胞骨架形态。
  • Wnt激活后ECM基因、交联基因及MMP抑制剂表达受抑,MMP1/9/14过表达。

核心结论

  • 在正常原代人小梁网细胞中,Wnt抑制后激活Wnt通路可逆转Wnt抑制所致的病理表型。
  • Wnt激活可能成为降低眼压的可行治疗策略。

研究设计与样本

  • 研究使用非青光眼供体来源的原代人小梁网细胞,体外培养12天。
  • 细胞分为三组:LGK974(Porcn抑制剂,10 µM)组、LY2090314(pGSK3β抑制剂,250 nM)组、以及LGK974处理9天后LY2090314处理3天组。
  • 采用Western blotting检测Wnt调控,定量PCR评估ECM相关基因,免疫荧光观察细胞骨架形态,原子力显微镜测定细胞刚度。

主要发现

  • Wnt激活经pGSK3β下调(0.3倍;P < 0.01)、AXIN2过表达(6.7倍;P < 0.001)和LEF1过表达(3.8倍;P < 0.001)证实。
  • Wnt抑制导致F-actin显著改变,后续Wnt激活可使其恢复。
  • Wnt抑制时细胞刚度为11.86 kPa(P < 0.01),后续Wnt激活后降至4.195 kPa(P < 0.01)。
  • Wnt激活后磷酸化YAP过表达1.8倍(P < 0.001),TAZ过表达1.4倍(P < 0.001)。
  • Wnt抑制后激活显著抑制ECM基因SPARC和CTGF(P < 0.01)、交联基因LOX和TGM2(P < 0.05)、MMP抑制剂TIMP1和PAI1(P < 0.001),并过表达MMP1/9/14(P < 0.01)。

临床怎么用

  • 在正常小梁网细胞中,先抑制后激活Wnt通路可逆转Wnt抑制相关病理改变,支持Wnt激活作为降眼压候选策略。
  • 该研究为体外细胞实验,尚需进一步在体研究验证Wnt激活降眼压的有效性与安全性。

局限性

  • 研究仅使用非青光眼供体来源的原代人小梁网细胞,未在青光眼细胞或动物模型中验证。
  • 实验为体外培养12天的短期观察,长期效果及在体安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Wnt is a spatiotemporally regulated signaling pathway whose inhibition is associated with glaucoma, elevated intraocular pressure (IOP), and cell stiffening. Whether such changes are permanent or may be reversed is unclear. Here, we determine if activation of Wnt pathway after inhibition reverses the pathologic phenotype. METHODS: Primary human trabecular meshwork (hTM) cells from nonglaucomatous donors were cultured for 12 days in the absence or presence of Wnt modulators: (i) LGK974 (Porcn inhibitor, 10 µM); (ii) LY2090314 (pGSK3β inhibitor, 250 nM); or (iii) 9 days of LGK974 followed by 3 days of LY2090314. Wnt modulation were determined by Western blotting and extracellular matrix (ECM) related genes were evaluated by quantitative PCR. Cytoskeletal morphology was determined by immunofluorescence and cell stiffness by atomic force microscopy. RESULTS: Wnt activation was confirmed by downregulation of pGSK3β (0.3-fold; P < 0.01), overexpression of AXIN2 (6.7-fold; P < 0.001), and LEF1 (3.8-fold; P < 0.001). Wnt inhibition resulted in dramatic changes in F-actin, which were resolved with subsequent Wnt activation. Concurrently, cell stiffness that was elevated with Wnt inhibition (11.86 kPa; P < 0.01) decreased with subsequent Wnt activation (4.195 kPa; P < 0.01) accompanied by significant overexpression of phosphorylated YAP (1.8-fold; P < 0.001) and TAZ (1.4-fold; P < 0.001). Additionally, Wnt activation after inhibition significantly repressed ECM genes (SPARC and CTGF, P < 0.01), cross-linking genes (LOX and TGM2, P < 0.05), inhibitors of matrix metalloproteinases (TIMP1 and PAI1, P < 0.001), and overexpressed MMP 1/9/14 (P < 0.01). CONCLUSIONS: These data strongly demonstrate that, in normal hTM cells, activation of the Wnt pathway reverses the pathological phenotype caused by Wnt inhibition and may thus be a viable therapeutic for lowering IOP.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Dhamodaran K, Baidouri H, Sandoval L, et al. Wnt Activation After Inhibition Restores Trabecular Meshwork Cells Toward a Normal Phenotype. Invest Ophthalmol Vis Sci. 2020. PMID: 32539133. doi:10.1167/iovs.61.6.30

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。